MICROVIABLE THERAPEUTICS
Mission & Vision
Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable’s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients’ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.
NEWS
You can follow the latest news of MicroViable in this section
Pilar Manrique, PhD contributed to opinion article at GEN News
Genetic Engineering and Biotechnolgy News is one of the leading journals in biotechnology, showcasing groundbreaking [...]
Microviable present at The Microbiome Times Partnering Forum
Microviable Therapeutics will be at The Microbiome Times Partnering Forum taking place in Brussels on [...]
Pilar Manrique will present at 9th Microbiome Movement Summit
Pilar Manrique, senior scientist at Microviable Therapeutics will be present at 9th Microbiome Microbiome Movement [...]
CONTACT

Get in touch with us for any questions using the following contact form.